Mitsubishi Tanabe Reports Initiation of P-III BouNDLess Trial in Patients with Fluctuating Parkinson’s Disease

 Mitsubishi Tanabe Reports Initiation of P-III BouNDLess Trial in Patients with Fluctuating Parkinson’s Disease

Shots:

  • The P-III BouNDLess study involves assessing of continuous carbidopa/levodopa (ND0612, SC) infusion vs immediate-release carbidopa/levodopa (CD/LD, PO) in 300 patients with PD experiencing motor fluctuations, evaluating its safety, efficacy and tolerability
  • Mitsubishi’s subsidiary NeuroDerm is leading the P-III study with primary objective to determine the effect of ND0612 on daily “GOOD ON” time as measured by a self-reported patient diary assessing motor function
  • ND0612 is a liquid formulation of carbidopa and levodopa administered subcutaneously for PD patients and has also shown safe and well tolerated results in P-I and P-II studies. Additionally, NeuroDerm plans to file its NDA to the UD FDA

Click here to read full press release/ article | Ref: Mitsubishi Tanabe | Image: Bioworld

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post